Stock TARA PROTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Delayed Nasdaq
Other stock markets
 14:48:03 29/04/2024 BST 		5-day change 1st Jan Change
2.992 USD +2.29% Intraday chart for Protara Therapeutics, Inc. -1.90% +59.57%
04-22 Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26 MT
04-05 Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26
MT
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
AQ
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
AQ
Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
CI
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
AQ
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
CI
Protara Therapeutics, Inc. Announces Resignation of Jathin Bandari as Chief Medical Officer, Effective April 11, 2024
CI
Protara Therapeutics: Q4 Earnings Snapshot
AQ
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Proteon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Top Premarket Gainers
MT
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Top Premarket Decliners
MT
Protara Therapeutics to Participate in Upcoming Investor Conferences
AQ
Top Premarket Decliners
MT
Protara Therapeutics Says 5 of 6 Patients in Dose Escalation Portion of Bladder Cancer Trial Showed Recurrence-Free Survival
MT
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TARA Stock
  4. News Protara Therapeutics, Inc.